Median Nonmedical Cost for Cancer Clinical Trial Participation Reaches $2,128
Cancer clinical trial participants who receive financial assistance for nonmedical costs are reimbursed a median total of $2,128 over the course of their enrollment, according to a study published November 9, 2026, in the peer-reviewed journal CANCER. The research highlights the specific logistical and socioeconomic barriers that often prevent patients from participating in oncology trials, despite the relatively low cost of removing those hurdles compared to the overall investment in drug development.
The analysis, led by Sukh Makhnoon, PhD, of UT Southwestern Medical Center, examined 2,826 individuals who received at least one reimbursement through the Lazarex Cancer Foundation between 2006 and 2024. These payments covered a variety of essential nonmedical expenses, including travel, lodging, meals, internet access, missed work, and caregiving costs for children or the elderly.
The Cost of Participation vs. Trial Investment
While the median reimbursement was $2,128, the median duration of participation for those in the study was 4.3 months. Reported data suggests that the average per-patient cost for oncology trials is approximately $60,000. Researchers noted that the modest reimbursement amount required to sustain patient participation represents a small fraction of the total trial expenditure, yet it remains a critical factor in patient retention and diversity.
The study found that the financial needs of participants often shifted during the trial. Monthly reimbursement amounts typically declined to approximately 60% of their initial levels by the third month of participation. This 40% drop suggests that the heaviest financial burden for patients occurs during the initial enrollment and screening phases, which often require frequent travel and time away from work.
Socioeconomic Disparities in Reimbursed Needs
The types of expenses reimbursed varied significantly based on patient income levels. Lower-income participants were more likely to seek reimbursement for ground transportation, internet access, and childcare. In contrast, higher-income patients received more reimbursement for airfare and lodging, indicating that geographic barriers may be more pronounced for those with higher baseline resources, while daily logistical costs are more pressing for lower-income individuals.
The timing of the study is significant given recent shifts in available support systems. The Lazarex Cancer Foundation, which provided the data for this 18-year analysis, suspended its CARE reimbursement program in August 2024. This suspension has raised concerns regarding the ongoing accessibility of trials for patients who cannot afford out-of-pocket nonmedical costs.
The findings indicate that without structured reimbursement programs, many patients may be forced to withdraw from trials due to accumulating costs that are not directly related to medical treatment. Dr. Makhnoon’s analysis suggests that stabilizing these financial supports could improve trial equity and completion rates without significantly increasing the overall cost of pharmaceutical research.
